Baclofen
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Baclofen: From Muscle Spasticity to Attention Deficit-Hyperactivity Disorder
One-Sentence Summary
Baclofen is a GABA-B receptor agonist well-established globally for the treatment of muscle spasticity associated with neurological conditions such as multiple sclerosis and spinal cord injury, though it is not currently registered in India. The TxGNN model predicts it may be effective for Attention Deficit-Hyperactivity Disorder (ADHD), with 0 registered clinical trials and 10 publications currently supporting this direction — the majority of which are preclinical animal studies or reviews focused on related neuropsychiatric conditions rather than ADHD directly.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Muscle spasticity (neurological disorders; based on global pharmacological profile — no India registration on record) |
| Predicted New Indication | Attention Deficit-Hyperactivity Disorder (ADHD) |
| TxGNN Prediction Score | 99.32% |
| Evidence Level | L4 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action (MOA) data was not available in this Evidence Pack. Based on Baclofen’s established global pharmacological profile, it acts as a selective GABA-B receptor agonist — binding to presynaptic GABA-B receptors and reducing neuronal excitability by inhibiting calcium influx and activating potassium conductance. This leads to decreased release of excitatory neurotransmitters and, critically for this prediction, suppression of mesolimbic dopamine neuron firing.
The theoretical basis for ADHD repurposing lies in the mesolimbic dopamine pathway: GABA-B agonism can reduce dopamine release in the nucleus accumbens and modulate corticostriatal circuits involved in impulse control and attentional regulation — the same circuits implicated in ADHD pathophysiology. Animal studies using spontaneously hypertensive rats (SHR), a validated ADHD preclinical model, have demonstrated that GABAergic agents measurably alter cortical-hippocampal EEG patterns and influence cost-benefit decision-making behavior, providing a neurobiological foothold for this hypothesis.
However, the existing literature supporting this prediction is largely indirect. Most publications relate to Tourette syndrome (which carries an approximately 60% ADHD comorbidity rate) or to general GABAergic neuromodulation, rather than ADHD-specific endpoints. Baclofen’s proven efficacy in alcohol use disorder — another dopamine dysregulation condition — offers additional mechanistic plausibility, but cross-indication translation to ADHD has not been tested in any completed human clinical trial. The species-to-human translational gap remains the central unresolved question.
Clinical Trial Evidence
Currently no related clinical trials registered for Baclofen in attention deficit-hyperactivity disorder.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35345730 | 2022 | Systematic Review / Meta-analysis | Cureus | Evaluates behavioral interventions, antipsychotics, and alpha agonists for tic disorders in Tourette’s syndrome; underscores the high prevalence of ADHD as a comorbidity requiring co-management |
| 24295630 | 2013 | Review | International Review of Neurobiology | Reviews emerging pharmacological strategies in Tourette syndrome; highlights GABA-B pathway modulation among candidates for comorbid ADHD-OCD presentations |
| 11393328 | 2001 | Review | Paediatric Drugs | Describes Tourette syndrome management options; identifies baclofen as an agent for tic suppression in patients with psychiatric comorbidity including ADHD |
| 10342599 | 1999 | Review | Journal of Child Neurology | Reports a 450-patient series treated with baclofen/botulinum toxin for tics; global tic severity assessed via Yale Global Tic Severity Scale — indirect but clinically grounded evidence of CNS activity in a condition closely linked to ADHD |
| 26366961 | 2015 | Review | Clinical Neuropharmacology | Reviews mood stabiliser use in paediatric autism spectrum disorders; discusses ADHD symptom overlap and pharmacological approaches relevant to attention dysregulation |
| 21300040 | 2011 | Animal Study (EEG) | Brain Research | In SHR rats (established ADHD model), centrally applied neurotransmitter agonists including GABAergic agents alter cortical and hippocampal EEG patterns; provides direct preclinical evidence of GABA system involvement in ADHD-like neurobiology |
| 24062084 | 2014 | Animal Study (In Vivo) | Psychopharmacology | α2A-adrenergic agonist guanfacine reduces impulsive decision-making via ventral hippocampus; contextualises the role of neuromodulatory systems (including GABAergic) in impulsivity relevant to ADHD |
| 24496320 | 2014 | Animal Study (In Vivo) | Neuropsychopharmacology | Dissects anterior cingulate cortex and amygdala contributions to effortful decision-making deficits associated with ADHD, schizophrenia, and depression; maps cognitive circuitry relevant to baclofen’s potential CNS targets |
| 30122296 | 2019 | Clinical Review | L’Encephale | Describes a supervised off-label prescribing framework for methylphenidate in adult ADHD in France; provides regulatory and clinical context for off-label pharmacotherapy development in ADHD |
| 24103016 | 2013 | Animal Study (In Vivo) | European Journal of Neuroscience | Habenular integrity is required for monoaminergic modulation of social play in rats; contributes to understanding dopaminergic/GABAergic circuit interplay relevant to ADHD-associated behavioural dysregulation |
India Market Information
Baclofen is not currently marketed in India. No product licenses or registered authorisations are on record. Any clinical use would require regulatory submission to CDSCO before the repurposing indication could be pursued domestically.
Safety Considerations
Drug Interactions (120 interactions identified; key interactions listed below):
| Interacting Drug | Severity | Clinical Implication |
|---|---|---|
| Morphine | Major | Additive CNS and respiratory depression; co-administration requires close monitoring |
| Morphine (liposomal) | Major | Same as morphine; formulation does not mitigate the interaction risk |
| Dronabinol | Moderate | Additive CNS depression; caution in patients using cannabinoids |
| Nabilone | Moderate | Additive CNS depression; similar to dronabinol |
| Metoclopramide | Moderate | May alter baclofen gastrointestinal absorption and onset of effect |
| Opium | Moderate | Additive CNS and respiratory depression |
| Sibutramine | Moderate | CNS serotonergic and noradrenergic interaction risk |
| Difenoxin | Moderate | Additive CNS depression via opioid pathway |
| Diphenoxylate | Moderate | Additive CNS depression; relevant in antidiarrhoeal co-prescribing |
Complete warnings and contraindications are not available in this Evidence Pack. Please refer to the package insert for full safety information before clinical use.
Conclusion and Next Steps
Decision: Hold
Rationale: No human clinical trials have been conducted specifically in ADHD populations, and the supporting literature consists entirely of animal studies and Tourette syndrome reviews with indirect relevance to ADHD. The mechanistic hypothesis is biologically plausible but unvalidated in humans, placing this candidate squarely at a preclinical evidence threshold (L4) that does not yet support advancement.
To proceed, the following is needed:
- MOA documentation: Obtain full mechanism of action data from DrugBank to formally substantiate the GABA-B → dopamine → ADHD circuit hypothesis
- Safety package: Download and parse the package insert (e.g., US FDA or EMA label) to complete warnings, contraindications, and special population data before any safety assessment can be initiated
- Proof-of-concept clinical data: Conduct a small Phase 1b/2a exploratory trial in adult ADHD patients measuring attention, impulsivity, and tolerability endpoints
- India regulatory pathway: File for CDSCO registration as a prerequisite to any Indian clinical development; assess whether a bridging study would be required
- Differentiation analysis: Clarify how Baclofen would position relative to existing ADHD pharmacotherapy (methylphenidate, amphetamines, atomoxetine, guanfacine) given its sedating CNS profile and major interactions with opioids
Note on secondary prediction: This Evidence Pack also identified Nicotine Dependence as a second-ranked predicted indication (TxGNN score 99.19%), supported by 3 Phase 2 clinical trials and 20 publications with an L2 evidence level and a “Proceed with Guardrails” recommendation. A separate focused report for that indication is advisable given the substantially stronger evidence base.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.